Abraham N.  Oler net worth and biography

Abraham Oler Biography and Net Worth

Mr. Avi Oler joined Onconova’s Management Team in December 2018 as Vice President, Corporate Development and General Counsel and was promoted to Senior Vice President, Corporate Development & General Counsel in January of 2020.

Mr. Oler served most recently as Vice President of Operations and Chief of Staff to the CEO of Spectrum Pharmaceuticals. During his tenure, he was instrumental in the company’s progress and productive licensing activities. He served in varied roles of increasing responsibility, as a member of the executive management team, the corporate development team, and as Head of Alliances and Legal Affairs.  Due to a series of successful accomplishments, he was named Chief of Staff.

Previously, Mr. Oler practiced corporate law at the law firm of Kirkland & Ellis LLP.  Prior to this, he was a financial research analyst at the Center for Financial Research & Analysis, and an investment banker with Lehman Brothers in London.

Mr. Oler holds a JD from Northwestern University School of Law with Distinction, an MBA from Kellogg School of Management with Distinction, and a Master of Science in Politics of the World Economy from the London School of Economics. He earned his undergraduate degrees, magna cum laude, from the Wharton School and the University of Pennsylvania.

What is Abraham N. Oler's net worth?

The estimated net worth of Abraham N. Oler is at least $0.00 as of November 25th, 2019. Mr. Oler owns 75,000 shares of Onconova Therapeutics stock worth more than $0 as of April 25th. This net worth evaluation does not reflect any other assets that Mr. Oler may own. Learn More about Abraham N. Oler's net worth.

How do I contact Abraham N. Oler?

The corporate mailing address for Mr. Oler and other Onconova Therapeutics executives is 375 PHEASANT RUN, NEWTOWN PA, 18940. Onconova Therapeutics can also be reached via phone at (267) 759-3680 and via email at [email protected]. Learn More on Abraham N. Oler's contact information.

Has Abraham N. Oler been buying or selling shares of Onconova Therapeutics?

Abraham N. Oler has not been actively trading shares of Onconova Therapeutics over the course of the past ninety days. Learn More on Abraham N. Oler's trading history.

Who are Onconova Therapeutics' active insiders?

Onconova Therapeutics' insider roster includes Steven Fruchtman (Insider), James Marino (Director), and Abraham Oler (SVP). Learn More on Onconova Therapeutics' active insiders.

Abraham N. Oler Insider Trading History at Onconova Therapeutics

See Full Table

Abraham N. Oler Buying and Selling Activity at Onconova Therapeutics

This chart shows Abraham N. Oler's buying and selling at Onconova Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Onconova Therapeutics Company Overview

Onconova Therapeutics logo
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.84
Low: $0.67
High: $1.01

2 Week Range

Now: N/A

Volume

1,281,800 shs

Average Volume

96,681 shs

Market Capitalization

$20.90 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.38